1 completed, 1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Toll-Like Receptor 9: new trials by email Literature Review of Toll-Like Receptor 9 trials Research Report on Toll-Like Receptor 9
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer Irreversible Electroporation (IRE), Nivolumab, Toll-Like Receptor 9 - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 | Unknown | Amsterdam UMC, location VUmc | 18 | 2020-09-01 | 2022-12-20 |
| Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT Pembrolizumab, SD-101, Leuprolide acetate - Prostatic Neoplasms | Phase 2 | Completed | David Oh | 23 | 2017-05-17 | 2025-12-05 |
Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Amsterdam UMC, location VUmc (1) · David Oh (1)
Netherlands (1) · United States (1)